MedCity News
MARCH 17, 2024
The U.S. Department of Justice has reportedly recently launched an antitrust investigation of UnitedHealth Group, which begs the question of whether the healthcare giant should be broken up. Experts have varying opinions.
Fierce Pharma
MARCH 20, 2024
Four months ago, when BioNTech slashed its 2023 revenue projection from 5 billi | When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. Sales came to 1.5 billion euros ($1.6 billion) for the fourth quarter and 3.8 billion euros ($4.1 billion) for 2023, coming up short of expectations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 18, 2024
FDA advisors have said that two BCMA-targeted CAR-T therapies can be used earlier in the treatment pathway for multiple myeloma, setting up FDA approvals for use in a broader patient population.
Pharmaceutical Technology
MARCH 18, 2024
Akums Drugs and Pharmaceuticals has introduced Hydroxyurea oral suspension, a room temperature-stable drug for treating sickle cell disease.
MedCity News
MARCH 19, 2024
AstraZeneca’s Fusion Pharmaceuticals acquisition is the latest in a wave of M&A activity that includes recent deals by Eli Lilly and Bristol Myers Squibb. The lead Fusion program is in mid-stage clinical development for treating advanced prostate cancer.
Fierce Pharma
MARCH 18, 2024
Two months after GSK sold a significant chunk of its stake in Haleon, Pfizer is | Two months after GSK sold a significant chunk of its stake in Haleon, Pfizer is prepared to do the same with a larger selloff, according to the consumer healthcare company. Pfizer is set to reduce its stake in Haleon from 32% to 24% by selling 630 million shares in a public offering.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
MARCH 21, 2024
A new £17.9 million strategic initiative is set to support UK advanced therapy medicinal product (ATMP) clinical trials, and help the region maintain its position as a leader in clinical research. An additional four years of funding for the Advanced Therapy Treatment Centre ( ATTC ) network is available through this programme. Collaborators include the National Institute for Health and Care Research (NIHR), Innovate UK, the ATTC network and the Cell and Gene Therapy Catapult (CGT Catapult).
MedCity News
MARCH 18, 2024
After a healthcare cyberattack, the impacted organization often doesn’t want to divulge a lot of information, Intermountain Health CISO Erik Decker said last week at HIMSS. However, he thinks healthcare organizations should be more transparent with their peers after an attack because “no one system operates independent of everybody else.
Fierce Pharma
MARCH 19, 2024
This year marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the company's red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian nat | 2024 marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the Danish drugmaker’s red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian nation.
pharmaphorum
MARCH 20, 2024
Vicore gets FDA breakthrough status for Almee, a cognitive behavioural therapy (CBT) digital health therapy used to support people with pulmonary fibrosis
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
MARCH 20, 2024
Lonza has agreed to acquire one of the world’s largest biologics manufacturing sites (by volume), for a total of $1.2 billion from Roche. The acquisition of the manufacturing facility will significantly increase Lonza’s capacity of the manufacture of large-scale biologics, to meet demand for commercial mammalian contract manufacturing. At present, the Genentech Vacaville facility in the US has a total bioreactor capacity of around 330,000 litres.
MedCity News
MARCH 21, 2024
Many people don’t take well to the term “healthcare consumer,” or have expressed that they prefer to be referred to as a patient rather than a consumer. But in the U.S., it’s a plain fact that people have choices when it comes to their healthcare. In this piece, three health system executives give their take on why “patient” and “consumer” are often one in the same — and why hospitals need to be mindful of this.
Fierce Pharma
MARCH 20, 2024
After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy (MLD) in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have | After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have broken new boundaries in pricing, too.
pharmaphorum
MARCH 21, 2024
A partnership between Eisai and Lifenet that aims to improve insurance cover for people with early dementia has generated its first policy, part of an effort by the pharma group to develop an ‘ecosystem’ to support patients.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
European Pharmaceutical Review
MARCH 19, 2024
Under a new deal, Novartis has agreed to acquire US-based biopharma company IFM Therapeutics, for a total of up to $835 million. As part of this new agreement, Novartis has exercised its option to acquire all outstanding capital stock of IFM Due, a subsidiary company of IFM. Therefore, under the acquisition, Novartis has full rights to IFM Due’s portfolio of small molecule Stimulator of Interferon Genes (STING) antagonists, IFM confirmed.
MedCity News
MARCH 22, 2024
Today, new digital solutions are emerging that provide tailored exercise programs and encourage small changes to daily life that can lead to significantly lower fall risk.
Fierce Pharma
MARCH 22, 2024
Sales are booming for Novo Nordisk’s GLP-1 treatments for diabetes and obesity. But that doesn’t mean the Danish company has moved on from its previous generation of blood sugar modulators. | With a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), Novo has come a step closer to bringing its revolutionary Awiqli (once weekly basal insulin icodec) to the market.
pharmaphorum
MARCH 22, 2024
Medicare has loosened restrictions on the reimbursement of obesity drugs, thanks to clinical data showing they can improve cardiovascular outcomes, but their price could be up for negotiation.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Commerce
MARCH 19, 2024
In an interview with Pharma Commerce Associate Editor Don Tracy, John Hoffman, Principal, Advocate for Success, LLC talks about his 'Health Equity Spotlight' panel and advocacy accomplishments.
MedCity News
MARCH 22, 2024
A CPO in the C-suite determines how a health system can move from a cost center to a revenue center with healthy operating margins by investing in specialty pharmacy services that reduce burden for healthcare staff and improve care for patients.
Fierce Pharma
MARCH 22, 2024
At a watershed moment for Duchenne muscular dystrophy (DMD) treatment, privately held Italian drugmaker Italfarmaco has added a new therapeutic option to the armamentarium against the debilitating | At a watershed moment for Duchenne muscular dystrophy treatment, privately held Italian drugmaker Italfarmaco has added a new therapeutic option to the armamentarium against the debilitating muscle-wasting disorder.
pharmaphorum
MARCH 22, 2024
First report from PHTI concludes that digital health technologies for diabetes management deliver minimal clinical benefit and raise healthcare costs
European Pharmaceutical Review
MARCH 18, 2024
A study has determined that intermittent low-intensity far-UVC light can inhibit mould growth below the threshold limit value of 23 mJ/cm 2. At 222nm, far-UVC light was shown to prevent development of common mould-producing fungi , specifically Penicillium candidum. The on-off duty cycle pattern of the far-UVC light used in the study is “consistent with its use in real-world settings”, the corresponding paper stated.
MedCity News
MARCH 21, 2024
Mirador Therapeutics applies machine learning to human data to discover new immunology and inflammation drugs. The startup’s management includes several from the executive team of Prometheus Biosciences, an immunology biotech bought by Merck last year.
Fierce Pharma
MARCH 20, 2024
As two of the world’s largest pharmaceutical companies, Johnson & Johnson and Pfizer have long been rivals in various therapeutic areas. | The company is accusing former employee Andrew Brackbill of downloading thousands of confidential strategy-related files before leaving for rival Pfizer.
Pharmaceutical Commerce
MARCH 18, 2024
In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the positive signs from rising activity levels in biopharma M&A— and what the momentum may mean for industry dealmaking and partnership efforts in the months ahead.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PM360
MARCH 22, 2024
AI-driven healthcare is making its way into our lives and with it comes positive changes Imagine a world where my AI emails your AI and they join forces to schedule our coffee chat. Next thing you know, we’re discussing campaign strategies over lattes, courtesy of our digital matchmakers. Welcome to the future, where AI in healthcare marketing isn’t just a concept— it’s the new normal.
MedCity News
MARCH 17, 2024
When you are a military nurse, you’re not just a clinical professional, you are also a soldier. Those roles take sacrifice, resilience, and courage. I urge leaders and policymakers to consider solutions to the crisis, including creating better incentives that will bolster the pipeline of students pursuing careers as military nurses.
Fierce Pharma
MARCH 20, 2024
After Johnson & Johnson last year changed its mind on its 2017 purchase of ap | Idorsia's Tryvio is the first oral anti-hypertensive therapy that uses a new therapeutic mechanism in nearly 40 years, suggesting the dawn of "a new era of endothelin research," the company said.
pharmaphorum
MARCH 21, 2024
Surgeons in the US have carried out the world’s first transplant of a pig kidney into a human, a feat made possible by genetic modification of the organ and an experimental immunosuppressant drug regimen to prevent rejection. The recipient, 62-year-old Richard Slayman of Weymouth in Massachusetts, had end-stage renal disease and was dependent on dialysis.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
141 
Let's personalize your content